论文部分内容阅读
目的32P一胶体内辐射治疗中晚期胃、食管癌的方法探索及疗效分析方法41例胃、食管癌，男33例，女8例，年龄45岁～74岁，平均年龄62．9岁，60岁以上为19例，诊断均由病理报告证实．其中鳞癌15例，腺癌26例．单纯食管癌16例，胃贲门癌25例．采用纤维内镜引导下瘤体内注射．注入瘤组织的32P-胶体的比活度依肿瘤大小略有不同，肿瘤直径＜2cm，放射性活度为0．5mCi～1．0mCi（18.5MBq一37MBq）体积不超过3．5mL．肿瘤直径在3cm～4cm或在5cm以上者，为2mCi～3mCi（74MBq一111MBq），体积不超过7mL．结果疗效：按照国际通用标准分为：完全缓解（CR）症状，体症完全消失4wk以上；部分缓解（PR）症状改善，肿瘤大小估计：缩小≥50％4wk以上，无变化（NC）病灶无明显变化4wk以上；进展（PD）新病灶出现或原有病变估计大于或等于25％，本组经2～4次治疗后经内镜检查或胃肠道钡剂造影复查，CR：8例占19．51％，PR：21例占51．22％，NC：4例，9．76％．PD：5例，12．19％．失访：3例，7．32％．CR＋PR有效者29例，总有效率达70．73％．生存期：随访38例至1977-12-31，2mo～5mo3例7．32％（3例均死于肝转移肝功能衰竭）．1a以上16例，41．46％．2a以上9例，21．95％．生存质量：随访41例中，吞咽困难消失16例，减轻3例
Objective 32P in-gel radiotherapy for the treatment of advanced gastric and esophageal cancer Methods and efficacy analysis Methods 41 cases of gastric and esophageal cancer, 33 males and 8 females, aged 45 to 74 years, mean age 62.9 years, 60 The cases were diagnosed by pathological reports. There were 15 cases of squamous cell carcinoma and 26 cases of adenocarcinoma. Simple esophageal cancer in 16 cases, gastric cardia cancer in 25 cases. Endoscopic injection under the guidance of fiber endoscope. The specific activity of the 32P-colloids injected into the tumor tissues was slightly different depending on the size of the tumor. The tumor diameter was <2 cm, and the radioactivity was 0.5 mCi to 1.0 mCi (18.5 MBq to 37 MBq). The volume did not exceed 3.5 mL. For tumors with a diameter of 3 cm to 4 cm or more than 5 cm, it is 2mCi to 3mCi (74MBq to 111MBq) and the volume does not exceed 7mL. Results Efficacy: According to the international standard, it was divided into: complete remission (CR) symptoms, physical symptoms completely disappeared over 4wk; partial remission (PR) symptoms improved, tumor size estimation: reduction ≥ 50% 4wk or more, no change (NC) lesions no Significant changes of more than 4wk; progress (PD) new lesions or the original lesions estimated to be greater than or equal to 25%, the group after 2 to 4 treatment after endoscopy or gastrointestinal tract angiography review, CR: 8 cases 19.51%, PR: 21 cases accounted for 51.22%, NC: 4 cases, 9.76%. PD: 5 cases, 12.19%. Lost: 3 cases, 7.32%. CR + PR effective in 29 cases, the total effective rate of 70.73%. Survival: Follow-up of 38 cases to 1977-12-31, 2mo～5mo3 cases of 7.32% (3 cases were all died of hepatic liver failure). More than 1a 16 cases, 41.46%. 2a above 9 cases, 21.95%. Quality of life: In 41 cases of follow-up, 16 cases of dysphagia disappeared and 3 cases eased